EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Early initiation of enzyme replacement therapy as facilitated by newborn screening improves health outcomes among patients with infantile-onset Pompe disease

Ankit K Desai, Eleanor Rodriguez-Rassi, Suhag Parikh, Rossana Sanchez Russo, David Kronn, J Austin Hamm, Irene J Chang, Damara Ortiz, Molly McPheron, Holly Lydigsen, Stephanie DeArmey, Sarah P Young und 1 weitere

Genetics in Medicine Open · 2026 · 4 · 103478

DOI: 10.1016/j.gimo.2025.103478 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genetics in Medicine Open, 2026. Verfasst von Ankit K Desai und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Lysosomal Disease Network, National Institutes of Health, Children's Hospital of Pittsburgh.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To assess the benefits of early enzyme replacement therapy (ERT) in patients with infantile-onset Pompe disease (IOPD).

Methods

A retrospective chart review of 17 IOPD (7 cross-reactive immunologic material [CRIM]-negative and 10 CRIM positive) who initiated ERT (alglucosidase alfa) ≤4 weeks of age and had ≥18 months follow-up was performed.

Results

Patients received starting doses of 20 mg/kg/every other week (n = 11), 20 mg/kg/week (n = 3), or 40 mg/kg/week (n = 3). Six CRIM-negative and 2 patients who were CRIM positive received immune tolerance induction (ITI) with Rituximab+Methotrexate+intravenous immunoglobulin. Five patients who were CRIM positive received transient low-dose methotrexate. All CRIM-negative patients were immune tolerant. Three patients who were CRIM positive developed high-sustained antibody titers (HSAT); 2 were immune tolerant after bortezomib-based ITI. One patient who was CRIM positive developed HSAT, was invasively ventilated, and succumbed at age 5.2 years. At the most recent follow-up (MRFU; 3.1-18.4 years), 16 patients were alive, ambulatory, feeding orally, invasive ventilator-free, and receiving high-dose ERT (median lifelong dose 2.76X; 1.36-4.00). All patients experienced left ventricular mass index and Glc4 reductions and for a subset, biomarkers were within normal limits at MRFU (left ventricular mass index:16/17, AST:9/17, CK:5/17, and Glc4:5/16).

Conclusion

These data highlight the benefits of early ERT initiation and ITI, along with high-dose ERT. Despite early treatment, patients with IOPD remain at risk of developing HSAT.

Schlagwörter

Stichwörter der Autor:innen

Enzyme replacement therapyImmune tolerance inductionNewborn screeningPompe disease

Autor:innen und Institutionen

  • Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC.
  • Aflac Cancer and Blood Disorders Center, Emory University School of Medicine, Atlanta, GA.
  • Department of Human Genetics, Emory University School of Medicine, Atlanta, GA.
  • Advanced Medical Genetics, Maria Fareri Children's Hospital at WMC Health, Hawthorne, NY.
  • Department of Pathology and Pediatrics, New York Medical College, Valhalla, NY.
  • East Tennessee Children's Hospital, Knoxville, TN.

Förderung

  • Lysosomal Disease Network
  • National Institutes of Health
  • Children's Hospital of Pittsburgh
  • National Institute of Neurological Disorders and Stroke
  • Cincinnati Children's Hospital Medical Center
  • National Center for Advancing Translational Sciences
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • Rare Diseases Clinical Research Network

Zitieren

APA

Desai, A. K., Rodriguez-Rassi, E., Parikh, S., Russo, R. S., Kronn, D., Hamm, J. A., Chang, I. J., Ortiz, D., McPheron, M., Lydigsen, H., DeArmey, S., Young, S. P., & Kishnani, P. S. (2026). Early initiation of enzyme replacement therapy as facilitated by newborn screening improves health outcomes among patients with infantile-onset Pompe disease. Genetics in Medicine Open, 4, 103478. https://doi.org/10.1016/j.gimo.2025.103478

Vancouver

Desai AK, Rodriguez-Rassi E, Parikh S, Russo RS, Kronn D, Hamm JA, et al. Early initiation of enzyme replacement therapy as facilitated by newborn screening improves health outcomes among patients with infantile-onset Pompe disease. Genetics in Medicine Open. 2026;4:103478. doi:10.1016/j.gimo.2025.103478

BibTeX
@article{Desai2026,
  author = {Desai, Ankit K and Rodriguez-Rassi, Eleanor and Parikh, Suhag and Russo, Rossana Sanchez and Kronn, David and Hamm, J Austin and Chang, Irene J and Ortiz, Damara and McPheron, Molly and Lydigsen, Holly and DeArmey, Stephanie and Young, Sarah P and Kishnani, Priya S},
  title = {Early initiation of enzyme replacement therapy as facilitated by newborn screening improves health outcomes among patients with infantile-onset Pompe disease},
  journal = {Genetics in Medicine Open},
  year = {2026},
  volume = {4},
  pages = {103478},
  doi = {10.1016/j.gimo.2025.103478}
}
Kostenlos starten →